Adicet Bio Inc - Asset Resilience Ratio

Latest as of March 2026: 59.83%

Adicet Bio Inc (ACET) has an Asset Resilience Ratio of 59.83% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ACET strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$101.35 Million
Cash + Short-term Investments

Total Assets

$169.38 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how Adicet Bio Inc's Asset Resilience Ratio has changed over time. See Adicet Bio Inc balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Adicet Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adicet Bio Inc (ACET) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $101.35 Million 59.83%
Total Liquid Assets $101.35 Million 59.83%

Asset Resilience Insights

  • Very High Liquidity: Adicet Bio Inc maintains exceptional liquid asset reserves at 59.83% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Adicet Bio Inc Industry Peers by Asset Resilience Ratio

Compare Adicet Bio Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Adicet Bio Inc (2008–2025)

The table below shows the annual Asset Resilience Ratio data for Adicet Bio Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 62.18% $119.61 Million $192.35 Million +7.78pp
2024-12-31 54.40% $119.81 Million $220.22 Million --
2023-12-31 0.00% $0.00 $207.29 Million --
2021-12-31 0.00% $0.00 $338.94 Million --
2020-12-31 6.69% $10.28 Million $153.84 Million -56.80pp
2019-12-31 63.48% $51.79 Million $81.59 Million -28.37pp
2018-12-31 91.86% $100.99 Million $109.94 Million +88.15pp
2017-12-31 3.71% $2.05 Million $55.19 Million +3.54pp
2016-12-31 0.16% $881.00K $540.78 Million -0.53pp
2015-12-31 0.70% $3.42 Million $489.77 Million +0.54pp
2014-12-31 0.16% $746.00K $467.98 Million -0.50pp
2013-12-31 0.66% $2.14 Million $323.43 Million +0.16pp
2012-12-31 0.51% $1.52 Million $299.28 Million +0.19pp
2011-12-31 0.32% $943.00K $294.99 Million +0.16pp
2010-12-31 0.15% $335.00K $216.56 Million -0.13pp
2009-12-31 0.29% $541.00K $189.27 Million +0.02pp
2008-12-31 0.27% $548.00K $205.50 Million --
pp = percentage points

About Adicet Bio Inc

NASDAQ:ACET USA Biotechnology
Market Cap
$75.72 Million
Market Cap Rank
#20665 Global
#4614 in USA
Share Price
$8.10
Change (1 day)
+4.38%
52-Week Range
$0.47 - $9.31
All Time High
$145.95
About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more